Progress, Potential, and Possibilities Podcast / Show Following The Unexpected Signals In Cancer Research - Dr. Alexander Shneider, Ph.D. - Founder and CEO, CureLab Oncology
Why do some scientific breakthroughs begin with ridicule?
In this episode, we explore cancer research, serendipity, and the philosophy behind unconventional biomedical innovation.
Dr. Alexander Shneider, Ph.D. is a biotech entrepreneur and scientist with more than three decades of experience spanning oncology, immunology, vaccines, and translational medicine. He is the Founder and CEO of CureLab Oncology ( https://www.curelaboncology.com/ ), where he is leading the development of a novel biological agent designed to fight cancer through a dual approach—stimulating anti-tumor immunity while also addressing the chronic inflammation that often underlies disease progression.
CureLab’s lead therapeutic, Elenagen, has demonstrated a strong safety profile and encouraging signals of clinical benefit in international Phase II studies, and is being explored both as an adjunct to standard cancer treatments and for its broader potential in inflammation-driven and age-associated diseases. The platform’s reach may extend beyond human medicine, with ongoing interest in applications for oncology in companion animals.
Over the course of his career, Dr. Shneider has advised biotechnology, pharmaceutical, and investment organizations across areas including R&D strategy, licensing, technology transfer, product development, and intellectual property. He previously founded CureLab, Inc., where he worked on tools for the rational design of DNA vaccines and the development of broad-spectrum influenza vaccine concepts.
In academia, Dr. Shneider has held professor-level appointments and led the Genetic Vaccine Laboratory at Sechenov University, where he helped establish multicenter clinical research infrastructure focused on diseases involving chronic inflammation. His research has also explored evolutionarily conserved RNA structures as targets for antiviral therapies and next-generation vaccine design.
In addition to his scientific and entrepreneurial work, he serves on the editorial boards of several peer-reviewed journals in immunology and aging research, reflecting his long-standing engagement at the intersection of basic science, clinical translation, and biotechnology innovation.
#CancerResearch #BiomedicalScience #CancerInnovation
#ScientificDiscovery #PhilosophyOfScience #Biotech #MedicalInnovation
#Oncology #BreakthroughScience #StartupScience #SciencePodcast #DrugDevelopment #Serendipity #Innovation #FutureOfMedicine